The rise of covalent proteolysis targeting chimeras.
Acrylamide
/ chemistry
Adenine
/ analogs & derivatives
Animals
Chimera
/ metabolism
Drug Discovery
Humans
Ligands
Molecular Docking Simulation
Piperidines
/ chemistry
Proteasome Endopeptidase Complex
/ chemistry
Protein Binding
Protein Conformation
Proteolysis
Signal Transduction
Structure-Activity Relationship
Ubiquitin-Protein Ligases
/ metabolism
Ubiquitination
Chemoproteomics
Covalent PROTACs
E3 ligases
Reversible covalent
Targeted degradation
Journal
Current opinion in chemical biology
ISSN: 1879-0402
Titre abrégé: Curr Opin Chem Biol
Pays: England
ID NLM: 9811312
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
21
10
2020
revised:
05
12
2020
accepted:
20
12
2020
pubmed:
8
2
2021
medline:
8
9
2021
entrez:
7
2
2021
Statut:
ppublish
Résumé
Targeted protein degradation offers several advantages over direct inhibition of protein activity and is gaining increasing interest in chemical biology and drug discovery. Proteolysis targeting chimeras (PROTACs) in particular are enjoying widespread application. However, PROTACs, which recruit an E3 ligase for degradation of a target protein, still suffer from certain challenges. These include a limited selection for E3 ligases on the one hand and the requirement for potent target binding on the other hand. Both issues restrict the target scope available for PROTACs. Degraders that covalently engage the target protein or the E3 ligase can potentially expand the pool of both targets and E3 ligases. Moreover, they may offer additional advantages by improving the kinetics of ternary complex formation or by endowing additional selectivity to the degrader. Here, we review the recent progress in the emerging field of covalent PROTACs.
Identifiants
pubmed: 33549806
pii: S1367-5931(20)30162-9
doi: 10.1016/j.cbpa.2020.12.003
pii:
doi:
Substances chimiques
Ligands
0
Piperidines
0
ibrutinib
1X70OSD4VX
Acrylamide
20R035KLCI
Ubiquitin-Protein Ligases
EC 2.3.2.27
Proteasome Endopeptidase Complex
EC 3.4.25.1
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
24-33Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.